title: Biochemical bone markers, bone mineral content, and bone mineral density in rats with experimental nephrotic syndrome.
abstract: The human nephrotic syndrome (NS) is accompanied by important alterations of mineral and bone metabolism. The purpose of the present study was to examine bone metabolism in rats with experimental NS and normal creatinine clearance, and to evaluate the reversibility of this alteration. NS was induced by three injections of puromycin aminonucleoside (PAN) on days 0, 21, and 35 (10, 5, and 5 mg/100 g body weight, respectively). The biochemical markers of bone formation (osteocalcin and alkaline phosphatase) and bone resorption (hydroxyproline and pyridinoline), bone mineral content (BMC), and bone mineral density (BMD), determined by dual-energy x-ray absorptiometry (DEXA), were studied on days 0, 7, 14, 28, 42, 56, 84, and 112. Proteinuria was present throughout the study. Hypoproteinemia was seen on days 7, 28, 42, and 56, returning to control values on days 84 and 112. In serum, osteocalcin (OC) concentration increased (p < 0.001), and alkaline phosphatase (ALP) decreased (p = 0.002). In urine, hydroxyproline increased (p < 0.001), but urinary pyridinoline was not different from the control group throughout the study. Increased serum parathyroid hormone concentration and decreased levels of 25-hydroxy and 1,25-dihydroxyvitamin D were found from day 7. During the intense proteinuria, bone resorption predominates and decreased BMC and BMD ensues in PAN-nephrotic rats. PAN-nephrotic rats showed low BMC and BMD compared to control group (p < 0.001). At the end of the study, when proteinuria persisted but total serum protein returned to control values, the biochemical bone markers, BMC, and BMD returned to normal. In conclusion, PAN-nephrotic rats had reversible bone alterations that were related to the magnitude of proteinuria and the concentration of total serum protein.
authors.affiliation: Department of Pediatrics, Children's Hospital, Cincinnati, Ohio, USA.
authors.forename: R I
authors.initials: RI
authors.lastname: Sierra
authors.forename: B L
authors.initials: BL
authors.lastname: Specker
authors.forename: F
authors.initials: F
authors.lastname: Jiménez
authors.forename: C
authors.initials: C
authors.lastname: Cruz
authors.forename: J
authors.initials: J
authors.lastname: Pedraza-Chaverrí
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D000596:Amino Acids / Q000652:urine; D000818:Animals; D015415:Biomarkers / Q000097:blood / Q000652:urine; D015519:Bone Density; D001842:Bone and Bones / Q000378:metabolism*; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D009404:Nephrotic Syndrome / Q000097:blood / Q000139:chemically induced / Q000378:metabolism* / Q000652:urine; D015675:Osteocalcin / Q000097:blood; D011507:Proteinuria / Q000378:metabolism; D011692:Puromycin Aminonucleoside / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000596:Amino Acids; D015415:Biomarkers; D015675:Osteocalcin; D011692:Puromycin Aminonucleoside; C015484:pyridinoline; D000469:Alkaline Phosphatase; D006909:Hydroxyproline